Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus. 

GlaxoSmithKline has published results from its latest Phase IIb trial of its investigational tuberculosis vaccine that show a subunit vaccine can reduce pulmonary TB, possibly leading the way for the first new vaccine for TB in over 90 years.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.